Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2

Medicine (Baltimore). 2021 May 14;100(19):e25923. doi: 10.1097/MD.0000000000025923.

Abstract

Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Anti-Infective Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Azithromycin / therapeutic use
  • COVID-19 / physiopathology
  • COVID-19 Drug Treatment*
  • Comorbidity
  • Critical Illness
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / physiopathology
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Interleukin-6 / antagonists & inhibitors*
  • Male
  • Middle Aged
  • RNA, Viral
  • Respiration, Artificial / statistics & numerical data
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Anti-Infective Agents
  • Antibodies, Monoclonal, Humanized
  • Interleukin-6
  • RNA, Viral
  • Hydroxychloroquine
  • Azithromycin
  • sarilumab